首页> The New England journal of medicine> Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.

导出 OA

翻译打印收藏纠错

第一作者： Jerald,Sadoff

第一单位： From Janssen Vaccines and Prevention, Leiden, the Netherlands (J. Sadoff, G. Shukarev, G. Scheper, M.L.G., H.S., J.V.H., M.D.); South African Research Council, Cape Town, South Africa (G.G.); Janssen Research and Development, Beerse, Belgium (A.V., C.T., H.F., B.S., K.O., M.F.R., N.C., T.T., K.H., J.R.G., F.S.); Janssen Research and Development, Spring House, PA (V.C.); Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro (B.G.); the University of Alabama at Birmingham, Birmingham (P.A.G.); the National Institute of Allergy and Infectious Diseases, Rockville (K.L.T., M.A.M.), Walter Reed Army Institute of Research, Silver Spring (M.L.R.), and the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (K.M.N.) - all in Maryland; Biomedical Advanced Research and Development Authority, Washington, DC (J.T.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston (D.H.B.); Janssen Research and Development, Raritan, NJ (J. Stoddard); and Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle (L.C.).

作者： Jerald,Sadoff ^[1] ; Glenda,Gray ^[1] ; An,Vandebosch ^[1] ; Vicky,Cárdenas ^[1] ; Georgi,Shukarev ^[1] ; Beatriz,Grinsztejn ^[1] ; Paul A,Goepfert ^[1] ; Carla,Truyers ^[1] ; Hein,Fennema ^[1] ; Bart,Spiessens ^[1] ; Kim,Offergeld ^[1] ; Gert,Scheper ^[1] ; Kimberly L,Taylor ^[1] ; Merlin L,Robb ^[1] ; John,Treanor ^[1] ; Dan H,Barouch ^[1] ; Jeffrey,Stoddard ^[1] ; Martin F,Ryser ^[1] ; Mary A,Marovich ^[1] ; Kathleen M,Neuzil ^[1] ; Lawrence,Corey ^[1] ; Nancy,Cauwenberghs ^[1] ; Tamzin,Tanner ^[1] ; Karin,Hardt ^[1] ; Javier,Ruiz-Guiñazú ^[1] ; Mathieu,Le Gars ^[1] ; Hanneke,Schuitemaker ^[1] ; Johan,Van Hoof ^[1] ; Frank,Struyf ^[1] ; Macaya,Douoguih ^[1] ; ENSEMBLE Study Group

作者单位： From Janssen Vaccines and Prevention, Leiden, the Netherlands (J. Sadoff, G. Shukarev, G. Scheper, M.L.G., H.S., J.V.H., M.D.); South African Research Council, Cape Town, South Africa (G.G.); Janssen Research and Development, Beerse, Belgium (A.V., C.T., H.F., B.S., K.O., M.F.R., N.C., T.T., K.H., J.R.G., F.S.); Janssen Research and Development, Spring House, PA (V.C.); Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro (B.G.); the University of Alabama at Birmingham, Birmingham (P.A.G.); the National Institute of Allergy and Infectious Diseases, Rockville (K.L.T., M.A.M.), Walter Reed Army Institute of Research, Silver Spring (M.L.R.), and the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (K.M.N.) - all in Maryland; Biomedical Advanced Research and Development Authority, Washington, DC (J.T.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston (D.H.B.); Janssen Research and Development, Raritan, NJ (J. Stoddard); and Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle (L.C.). ^[1]